RxDoctor Payments Data

James Lee, DPM

Podiatrist · Palm Springs, CANPI 1437253663

Payments from drug & device makers

$4,239in general payments, 2019–2025

Across 34 payments — averaging $124.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$2K
  • Paragon 28, Inc.$2K
  • Stryker$285
  • Averitas Pharma Inc.$140
  • Cardiovascular Systems Inc.$95
  • Organogenesis Inc.$64
  • plus $91 from 4 others

What the payments were for

  • Travel & lodging$2,23553%
  • Food & beverage$1,35132%
  • Other$65215%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,239 in reported general payments places this provider in the 80th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$152,533
Medicare patients
447
Services billed
1,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox561$11,227
SantylCollagenase Clostridium Hist.15$5,249
Econazole Nitrate101$3,819
Diclofenac Sodium40$636
Clotrimazole14$400
Ondansetron Hcl13$372
Clindamycin Hcl36$342
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$183
Silver Sulfadiazine21$152
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$133
Doxycycline Hyclate11$118
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$90
SsdSilver Sulfadiazine11$89
Gabapentin20$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$33$5,24915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 721 podiatrist providers in California.

Other podiatrist in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →